Recent Updates
Recently added Catalysts
ATYR Neutral Sentiment

EFZO-FIT™, the Largest Placebo-Controlled Trial in Pulmonary Sarcoidosis

Key Takeaway: aTyr Pharma is conducting the EFZO-FIT™ trial, the largest placebo-controlled study for pulmonary sarcoidosis. This trial aims to evaluate the efficacy of efzofitimod in patients with this condition. The study's design and scope highlight the company's commitment to addressing unmet medical needs in pulmonary sarcoidosis.
Price reaction · baseline $3.27 (2025-05-16 close) · hit pre-market · 2 other ATYR headline(s) in the window, move may be shared
day 0 close
+5.2%
day 1
+6.7%
day 3 · peak
+16.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
5.7%
average across 7 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kg
Phase 3 · Pulmonary Sarcoidosis

Full Press Release Details

• Company About Us Leadership Team Board of Directors Advisors Contact
• Our Science Extracellular t RNA Synthetase Biology Intellectual Property Publications, Posters and Presentations
• R&D Pipeline Efzofitimod Research Programs Pangu
• Patients Clinical Trials About Pulmonary Sarcoidosis About SSc-ILD EFZO-CONNECT ™ Expanded Access Policy
• Careers Working at aTyr Career Opportunities
• Investors and Media Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Analyst Coverage Investor Alerts Events and Webcasts Media
• Privacy Policy
• About Us
• Leadership Team
• Board of Directors
• Advisors
• Contact
• Extracellular t RNA Synthetase Biology
• Intellectual Property
• Publications, Posters and Presentations
• Pipeline
• Efzofitimod
• Research Programs
• Pangu
• Clinical Trials
• About Pulmonary Sarcoidosis
• About SSc-ILD
• EFZO-CONNECT ™
• Expanded Access Policy
• Working at aTyr
• Career Opportunities
• Corporate Governance Board of Directors Board Committees
• News Releases
• SEC Filings
• Stock Information
• Analyst Coverage
• Investor Alerts
• Events and Webcasts
• Media
• Board of Directors
• Board Committees
Last updated: May 19, 2025